Published online May 16, 2021. doi: 10.12998/wjcc.v9.i14.3327
Peer-review started: October 7, 2020
First decision: January 17, 2021
Revised: January 24, 2021
Accepted: March 4, 2021
Article in press: March 4, 2021
Published online: May 16, 2021
Processing time: 188 Days and 17.2 Hours
Acute flaccid paralysis (AFP) and neurogenic respiratory failure rarely occur in children. At the end of 2018, some children with such symptoms were admitted to our hospital. In this study, we aimed to assess two children with AFP and neurogenic respiratory failure associated with enterovirus D68 (EV-D68).
Two children admitted to our hospital presented with symptoms and imaging results different from those of acute disseminated encephalomyelitis and hand, foot, and mouth disease. Their main symptoms were AFP and neurogenic respiratory failure. Magnetic resonance imaging showed severe inflammatory injury mainly to the anterior horn cells of the spinal cord. Blood and cerebrospinal fluid samples were collected to assess for pathogens, including bacteria, tuberculosis, cryptococcus, herpes virus, and coxsackie virus, and the results were negative. At the beginning, the two cases were not assessed for EV-D68 in the nasopharyngeal, blood, and cerebrospinal fluid specimens. About 2 mo later, EV-D68 was detected in the stool sample of one of the cases. The symptom of AFP was caused by injury to the anterior horn cells at levels C5-L5 of the spinal cord, while neurogenic respiratory failure was at levels C3-C5.
We should pay attention to the detection and diagnosis of EV-D68 and make efforts to develop antivirus drugs and vaccines.
Core Tip: This paper reports two pediatric cases of acute flaccid paralysis (AFP) and neurogenic respiratory failure associated with enterovirus D68 (EV-D68) infection which rarely occur. We found that EV-D68 might have caused inflammatory injury to the anterior horn cells of the spinal cord. AFP was caused at levels C5-L5, while neurogenic respiratory failure was caused at levels C3-C5. Our findings indicate that EV-D68 should be carefully monitored in children and that further research must be carried out to develop special antivirus drugs and vaccines. We believe that our research is of particular interest and use to clinicians and experts in infectious diseases.